Combination therapy using a LIV1-ADC and a chemotherapeutic
The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.
1. A method for treating a subject having cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and a checkpoint inhibitor, wherein the LIV-1-ADC comprises a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E.
2. The method of claim 1 , wherein the subject has breast cancer.
3. The method of claim 2 , wherein the breast cancer is triple negative breast cancer, triple positive breast cancer, HER2-positive breast cancer, or hormone receptor positive cancer.
4. The method of claim 3 , wherein the subject has triple negative breast cancer.
5. The method of claim 1 , wherein the subject has prostate cancer, ovarian cancer, endometrial cancer, pancreatic cancer, lung cancer, a cervical cancer, a melanoma, or squamous cell carcinoma.
6. The method of claim 1 , wherein the LIV-1-ADC is administered at a dosage between 1.5 mg/kg and 4 mg/kg of the subject's body weight.
7. The method of claim 1 , wherein the LIV-1-ADC is administered at a dosage of 2.5 mg/kg of the subject's body weight.
8. The method of claim 1 , wherein the LIV-1-ADC is administered once every 3 weeks.
9. The method of claim 1 , wherein the LIV-1-ADC is administered by intravenous injection.
10. The method of claim 1 , wherein the checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, B7-DC-Fc, LAG3, or TIM3.
11. The method of claim 10 , wherein the checkpoint inhibitor is an anti-PD-1 antibody.
12. The method of claim 11 , wherein the anti-PD-1 antibody is MEDI0680, AMP-224, nivolumab, pembrolizumab, or pidilizumab.